miRNAs are involved in many physiologic and disease processes by virtue of degrading specific mRNAs or inhibiting their translation. miR-148a has been implicated in the control of tumor growth and cholesterol and triglyceride homeostasis using in vitro or in vivo gene expression- and silencing-based approaches. Here miR-148a knockout (KO) mice were used to investigate the intrinsic role of miR-148a in liver physiology and hepatocarcinogenesis in mice. miR-148a downregulation was found to be correlated with poor clinical outcomes in hepatocellular carcinoma (HCC) patients. Under regular chow diet (RCD) or high fat diet (HFD), miR-148a deletion significantly accelerated DEN-induced hepatocarcinogenesis in mice. Mechanistically, miR-148a deletion promotes lipid metabolic disorders in mice. Moreover, restoration of miR-148a reversed these defects. Finally, miR-148a was found to directly inhibit several key regulators of hepatocarcinogenesis and lipid metabolism. These findings reveal crucial roles for miR-148a in the hepatic lipid metabolism and hepatocarcinogenesis. They further identify miR-148a as a potential therapeutic target for certain liver diseases, including cancer.

Results

miR-148a downregulation predicts poor HCC patient clinical outcomes. In our previous studies, miR-148a significantly inhibited HCC cell growth. However, the molecular mechanisms of miR-148a in liver physiology and hepatocarcinogenesis remain poorly understood. To address the physiological roles of miR-148a in the liver, a KO mouse model with a germline deletion of miR-148a was used. Our studies show that miR-148a is crucial for hepatic metabolism. It also possesses an intrinsic tumor suppressor function in the DEN-induced hepatocarcinogenesis model.
with HL7702 and FHCC98 (Supplementary Figure 1b). Also Pri/Pre-miR-148a and miR-148a-3p were significantly downregulated in HCC samples compared with paired normal hepatic tissues (Figure 1b). Furthermore, decreased miR-148a expression was significantly associated with advanced stage tumors in HCC patients (Figure 1c). Histologically poorly differentiated HCC also showed a significant association with decreased miR-148a-3p expression relative to well differentiated tumors (Figure 1d). To confirm the above results, the publicly available TCGA datasets of HCC cases were analyzed. In accordance with the above results, miR-148a-3p/5p expression in HCCs was significantly lower than that in normal hepatic tissues (Figure 1e) and the significant association between decreased miR-148a-3p/5p expression and advanced tumor stage was also validated (Figure 1f). To further study the clinical significance of miR-148a expression, the survival rates in TCGA data set of HCC were assessed. HCC patients were assigned to two groups based upon their miR-148a-3p and 5p expression levels using the minimum P-value approach, which is a comprehensive method to identify the optimal risk separation cutoff point in continuous gene expression measurements for survival analysis. The cutoff values for high and low miR-148a-3p and 5p expression groups were 88639 and 97.73 per million in TCGA data set, respectively. In HCC patients, those with low expression of miR-148a-3p/5p had significantly worse survival than those with high miR-148a-3p/5p expression (Figure 1g). These findings suggest that decreased miR-148a-3p/5p expression is involved in the pathogenesis of HCC.

**miR-148a inhibits tumor growth and lung colonization.** We investigated whether miR-148a inhibits HCC progression as suggested by its patterns of expression in human HCC patients with different survival statistics. Because FHCC98 and HepG2 HCC cell lines show high and low levels of miR-148a-3p expression, respectively, FHCC98 cells stably expressing forced miR-148a-3p sponge and HepG2 cells stably expressing Pri-miR-148a were established. Inhibition and overexpression of miR-148a-3p were confirmed by RT-qPCR (Supplementary Figure 2a). To investigate the role of miR-148a on tumor growth, an orthotopic liver cancer model was used. As shown in Supplementary Figure 2b and c, the tumors formed by miR-148a-3p sponge-expressing FHCC98 cells were bigger than those formed by control FHCC98 cells. In contrast, tumors formed by Pri-miR-148a expressing HepG2 cells were significantly smaller than the tumors formed by control HepG2 cells. To assess whether miR-148a-3p also affects lung colonization, we directly injected the above cell lines via tail vein into nude mice and measured

---

**Figure 1** miR-148a is downregulated in HCC, and low expression predicts poor HCC patient outcomes. (a) miR-148a expression across mouse tissues of 2-week and 8-week old mice. Data present mean ± S.D. (b) Expression of Pri/Pre-miR-148a and miR-148a-3p in 78 HCC samples and their adjacent noncancerous tissues. (a-b) Pri/Pre-miR-148a and miR-148a-3p RNA levels normalized for U6 were measured by stem-loop RT-qPCR in RNA purified from the above tissues. (c and d) Association of miR-148a-3p expression with clinical stages (c) and tumor differentiation (d) in sporadic HCC samples. (e) miR-148a-3p/5p expression in normal liver and HCC tissues from TCGA data set. (f) Association of miR-148a-3p/5p expression with clinical stages in HCC patients from TCGA data set. (b-f) Significance was performed using Wilcoxon signed rank test. The horizontal lines in the box plots represent the median, the boxes represent the interquartile range, and the whiskers represent the minimal and maximal values. (g) Survival of human HCC patients from TCGA data set with high versus low miR-148a-3p/5p expression. P-values and hazard ratios (HR) are indicated.
lung colonization 8 weeks later. As shown in Supplementary Figure 2d–f, miR-148a-3p inhibition in FHCC98 cells increased lung colonization whereas Pri-miR-148a overexpression in HepG2 cells significantly decreased lung colonization incidence. These results suggest that miR-148a inhibited both tumor growth and lung colonization.

miR-148a deletion promotes DEN-induced hepatocarcinogenesis in mice. To determine the effect of miR-148a deletion on hepatocarcinogenesis, a DEN-induced mouse HCC model was used. Wild type (WT) and miR-148a knockout (KO) male mice were treated with DEN at postnatal day 15 on either RCD or HFD (Figure 2a). Then miR-148a KO mice were randomly divided into two groups. One group was treated with concentrated pHAGE-Pri-miR-148a lentivirus and the other group was treated with concentrated pHAGE-GFP lentivirus (Figure 2a). Strikingly, the number of tumor nodules per liver were significantly higher in miR-148a KO mice than in WT mice (Figure 2b–d) and tumor sizes were bigger (Figure 2e) irrespective of the animals’ diet. Moreover, restoring Pri-miR-148a expression reduced the size of tumor nodules and also tumor growth rates (Figure 2b–e) in miR-148a KO liver. These findings suggested that miR-148a deletion promotes hepatic tumor progression in mice.

miR-148a deficiency enhances hepatic steatosis. Excessive lipid anabolism and storage caused by deregulation of lipid and cholesterol metabolism are now increasingly recognized to promote hepatocarcinogenesis.2,23 Given that miR-148a deficiency also enhances hepatocarcinogenesis, hepatic steatosis in these animals was assessed by quantification of hepatic neutral lipid by ORO staining in hepatic tissues. As shown in Figure 3a and b, miR-148a KO mice exhibited significantly increased hepatic steatosis as indicated by lipid accumulation. The expression of genes involved in lipogenesis and fatty acid uptake24 were also significantly upregulated in miR-148a KO mice (Figure 3c and d).

The profiles of other lipid metabolites in the serum and liver from WT and miR-148a KO mice were also measured. Regardless of the diet, miR-148a deletion led to significant increases in serum and hepatic total cholesterol (TC) without significantly altering triglyceride (TG) levels (Figure 4a and b, Supplementary Table 2). Similarly, DEN-treated miR-148a KO mice also exhibited significantly elevated serum and hepatic TC without significantly changing TG levels on either RCD or HFD (Figure 2a and Figure 4a and b,Supplementary Table 2). As hepatic and serum TC levels were increased without a significant change in TG levels in miR-148a KO mice, the increase of TC levels could be the result of increased TC biosynthesis in miR-148a KO mice. Therefore, the expression of cholesterol biosynthetic genes was measured by RT-qPCR. The results showed that most genes in this pathway were more highly expressed in miR-148a KO animals, including those encoding sterol regulatory element binding transcription factor 2 (Srebf2) and the rate-limiting enzyme, 3-hydroxy-3-methylglutaryl-CoA reductase (Hmgcr; Figure 4c). These findings strongly support that miR-148a deficiency increases cholesterol biosynthesis.

miR-148a targets Hmgcr, Pgc1α, Sirt7 and Ybx1. As described above, miR-148a deletion enhances lipid metabolism and hepatocarcinogenesis. To identify potential targets of miR-148a-3p/5p, database prediction combined with biological function analyses were performed on candidate target genes involved in lipid metabolism and hepatocarcinogenesis. Pparg co-activator 1 alpha (Pgcr1α), sirtuin 7 (Sirt7) and Hmgcr, Y-box binding protein 1 (Ybx1) which are
Figure 3  Loss of miR-148a causes hepatic lipid accumulation. (a and b) Left: Representative images of ORO-stained liver histological sections from the WT and miR-148a KO mice fed a RCD or HFD with or without DEN treatment. Right: Quantifications of the lipid droplets (LDs) volumes from the areas of ORO-stained liver sections. (c-d) RT-qPCR analysis of the RNA levels of hepatic genes involved in lipogenesis (c) and fatty acid (FA) uptake (d) in the mice from (a and b). Data present mean ± S.D. *P < 0.05; **P < 0.01; ***P < 0.001

Figure 4  miR-148a deletion enhances cholesterol biosynthesis. (a and b) Serum (a) and hepatic (b) TC in the WT and miR-148a KO mice under RCD or HFD with or without DEN treatment (n=5–7). Significance was performed using Wilcoxon signed rank test. The horizontal lines in the box plots represent the median, the boxes represent the interquartile range, and the whiskers represent the minimal and maximal values. (c) RT-qPCR analysis of the expression of hepatic genes involved in cholesterol biosynthesis in the mice from (a). Data present mean ± S.D. in (c). *P < 0.05; **P < 0.01; ***P < 0.001
involved in the processes of lipid metabolism and hepato-
carcinogenesis were all identified as potential targets of miR-148-3p and 5p, respectively.25–29 Pgc1α is a transcrip-
tion co-activator that regulates numerous genes involved in
lipid and energy metabolism.25 Sirt7 controls lipid metabolism
in liver by regulating the ubiquitin-proteasome pathway.26
Hmgcr is the rate-limiting enzyme for cholesterol synthesis.27
Ybx1 is a DNA and RNA binding protein and has been
implicated in numerous cellular processes including regula-
tion of transcription and translation, pre-mRNA splicing, DNA
repair and mRNA packaging.28,29

To study the effect of miR-148a-3p/5p on endogenous
expression of these targets, their mRNA and protein levels in
the livers of WT and miR-148a KO mice were measured and
found to be elevated in the latter group (Figure 5a and b). To
determine whether these targets represent direct targets of
miR-148a-3p/5p, luciferase reporter assays were conducted
to examine whether the putative miR-148a-3p/5p-binding sites in
the 3′UTR of these targets were important for miR-148a-mediated
suppression. Indeed, enforced miR-148 expression inhibited
the activity of these targets 3′UTR reporter vector in dual
luciferase reporter assays, while mutation in miR-148a binding
sites abrogated this repression; Suppression of miR-148a-3p
and 5p using their respective sponge or inhibitor enhanced the
activity of Pgc1α, Sirt7 and HMGCR, YBX1 3′-UTR reporter
vector in the same assays, respectively, while mutation in
miR-148a-3p/5p-binding sites abrogated this upregulation
(Figure 5c). These results suggested that the mRNAs of
these targets are directly regulated by miR-148a-3p/5p via
seeded-matching sequences.

Finally, we used an antibody against AGO-2 to co-
immunoprecipitate RNAs associated with the RNA-induced
Silencing Complex (RISC). As shown in Figure 5d and e, the
above target RNAs were significantly enriched in WT liver
extracts versus those from miR-148a KO mice. Taken
together, these data indicated that miR-148a-3p/5p directly
targets these molecules.

Discussion
In this study, the intrinsic physiological function of miR-148a
was investigated using mice with germline deletion of
the miR-148a locus. miR-148a is downregulated in HCCs
and is associated with poor prognosis as we and others
have shown previously. Many studies including ours have
shown that miR-148a performs a tumor suppressor function
in human HCCs.13–20 In cultured HCC cells and mouse
xenograft models, miR-148a suppressed growth, epithelial-
to-mesenchymal transition, invasion and metastasis through
inhibition of different oncprotein signaling pathways.13–20 In
the current study, miR-148a exerted an intrinsic tumor suppressor effect as shown by several pieces of evidence. First, miR-148a deficiency promoted DEN-induced hepatocarcinogenesis through multiple complex mechanisms in mice and the re-expression of miR-148a via lentivirus infection reversed this tumor susceptibility. This is likely mediated by the ability of miR-148a to directly and indirectly inhibit the expression of multiple, functionally related genes, which encode key factors that promote HCC progression such as c-Myc, Dnmt1, Wnt1, Ybx1, SirT7 and Pgc1α. Restoration of miR-148a expression is sufficient to inhibit DEN-induced hepatocarcinogenesis in mice. Recently it has been shown that miR-148a-A-mimetic treatment in Pten null mice markedly suppressed tumor development and growth rates.19 These effects were associated with tumor cell differentiation and were at least partially mediated by IkB kinase alpha/NUMB/NOTCH signaling.19 Therefore, miR-148a may represent a promising candidate for miRNA replacement therapy in HCC patients.

Our study also revealed that genetic deletion of miR-148a results in hepatic lipid accumulation and increased serum and liver TC levels. These abnormalities correlated with the upregulation of several key genes whose encoded products catalyze lipogenesis and cholesterol biosynthesis. These include Hmgcr the rate-limiting enzyme of cholesterol biosynthesis and a direct miR-148a target, and other enzymes downstream of Hmgcr. miR-148a deletion also resulted in increased expression of several key factors involved in hepatic lipid metabolic transcriptional regulation, including Pgc1α and SirT7. Therefore, miR-148a KO mice have abnormal hepatic lipid metabolism. Patients with hepatitis or cirrhosis also tend to have high levels of TC as well as a greatly increased risk of developing HCC.2,23

In summary, we show that miR-148a deletion exerts crucial roles on lipid metabolism and hepatocarcinogenesis. These data further identify miR-148a as a potential therapeutic target for certain liver diseases, including cancer.

Materials and Methods

Materials. DEN (73861) and HFD (D12492) were ordered from Sigma-Aldrich and Research Diets, respectively. Genomic DNA from mouse tails was isolated using the Wizard Genomic DNA Purification Kit (A1120) (Promega, Madison, WI, USA). miR-148a-5p inhibitor was purchased from RiboBio Co., Ltd. (Guangzhou, China) poly-antibody, or anti-SIRT7 (12994-1-AP, Proteintech, Wuhan, Hubei, China) poly-antibody, or anti-PGC1 antibody (1:1000) (ab76149, Abcam), or with a 1:1,000 dilution of anti-HMGCR (A20658-1-AP, Proteintech, Wuhan, Hubei, China) poly-antibody, or anti-SIRT7 (12994-1-AP, Abcam) poly-antibody as described. The blot was then incubated with a 1 : 5,000 dilution of HRP-conjugated goat anti-mouse IgG (Santa Cruz Biotechnology), washed, and subjected to chemiluminescence detection as described.20,21

Bioinformatics and statistical analyses. Online databases Targetscan (http://www.targetscan.org/), miRDB (http://www.mirdb.org), miRwalk (http://www.ma.uni-heidelberg.de/apps/zmt/mirwalk/), PICTAR5 (http://picTar.mdc-berlin.de/) and miRanda (http://www.miranda-mi.org) were used to predict miR-148a targets. TCGA data analysis was performed as described previously.24,25 HCC datasets were downloaded from the Cancer Genome Atlas (TCGA) data portal (http://tcga-data.nci.nih.gov/).26,27 MiR-148a expression data were assessed and Kaplan–Meier curves were analyzed in human HCC tissues from the TCGA miR-seq data set (n = 355). HCC samples were assigned to two groups based on miR-148a-3p/5p expression level using the minimum P-value approach.27 Significance within the high and low expression groups was calculated using a two-sided t-test.

Data were expressed as the mean ± S.D. or S.E.M. Statistical analysis was performed using the unpaired, two-tailed Student’s t-test, Wilcoxon signed rank test, or Mann–Whitney U-test and P < 0.05 was considered statistically significant.28,29

Conflict of Interest

The authors declare no conflict of interest.
Acknowledgements. This study was supported by grants from the National Natural Science Foundation of China (81472549), the 973 Program of China (2014CB110600, 2016YFC1302300, 2011CB944104), the Fundamental Research Funds for the Central Universities (090314380004) and the Natural Science Foundation for Universities in Jiangsu Province (BK20151396).

1. Eulalio A, Huntzinger E, Izaurralde E. Getting to the root of miRNA-mediated gene silencing. Cell 2009; 135:867–872.
2. Marquardt JU, Andersen JB, Thorgeirsson SS. Functional and genetic deconstruction of the cellular origin in liver. Nat Rev Cancer 2015; 15: 653–667.
3. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002; 31: 339–346.
4. Zhang JP, Zeng C, Xu L, Gong J, Fang JH, Zhuang SM. MicroRNA-148a suppresses the invasiveness of transformed cells. Mol Carcinog 2014; 584: 653–667.
5. Sekine S, Ogawa R, Ito R, Hiraoka N, McManus MT, Kanai Y. Ablation of Dicer1 induces dysregulated fetal gene expression and promotes hepatocarcinogenesis. Gastroenterology 2009; 136: 2304–2315.
6. Han, NJ, Master ZR, Eaudaille SF, Werblat DE, Matthews RP, Friedman JR. The microRNA-30 family is required for vertebrate hepatoblast development. Gastroenterology 2009; 136: 1081–1090.
7. Tats WC, Hsu SD, Hsu CS, Lai TC, Chen SJ, Shen R et al. MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J Clin Invest 2012; 122: 2894–2897.
8. Hsu SH, Wang B, Kofa J, Yu J, Costinean S, Kutsy H et al. Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J Clin Invest 2012; 122: 2871–2883.
9. Wen J, Friedman Jr. miR-122 regulates hepatic lipid metabolism and tumor suppression. J Clin Invest 2012; 122: 2773–2776.
10. Wagschal A, Najafi-Shoushtari SH, Wang L, Goedeke L, Sinha S, deLemos AS et al. Genome-wide identification of microRNAs regulating cholesterol and triglyceride homeostasis. Nat Med 2015; 21: 1290–1297.
11. Goedeke L, Rottman N, Carfraín-Duque A, Aranda JF, Ramirez CM, Araldi E et al. MicroRNA-146a regulates LDL receptor and ABCA1 expression to control circulating lipoprotein levels. Nat Med 2015; 21: 1280–1289.
12. Goedeke L, Wagschal A, Fernandez-Hernando C, Nájar AM. miRNA regulation of LDL-cholesterol metabolism. Biochim Biophys Acta 2016; 1861: 2047–2052.
13. Xu X, Fan Z, Kang L, Han J, Jiang C, Zheng X et al. Hepatitis B virus X protein represses miRNA-146a to enhance tumorigenesis. J Clin Invest 2013; 123: 630–645.
14. Gailhouste L, Gomez-Santos L, Hijikawa K, Hatada I, Kitagawa N, Kawaihara K et al. miR-148a plays a pivotal role in the liver by promoting the hepatospecific phenotype and suppressing the invasiveness of transformed cells. Hepatology 2013; 58: 1135–1146.
15. Yan H, Dong X, Zhong X, Ye J, Zhou Y, Yang X et al. Inhibitions of epithelial to mesenchymal transition and cancer stem cells-like properties are involved in miR-148a-mediated anti-metastasis of hepatocellular carcinoma. Mol Carcinog 2014; 53: 960–969.
16. Zhang JP, Zeng C, Xu L, Gong J, Fang JH, Zhuang SM. MicroRNA-148a suppresses the epithelial-mesenchymal transition and metastasis of hepatoma cells by targeting Met/Stat3 signaling. Oncogene 2014; 33: 4083–4076.
17. Long XR, He Y, Huang C, Li J. MicroRNA-148a is silenced by hypermethylation and interacts with DNA methyltransferase 1 in hepatocarcinogenesis. Int J Oncol 2014; 44: 1915–1922.
18. Li L, Liu Y, Guo Y, Liu B, Zhao Y, Li P et al. Regulatory MiR-148a-ACVR1/BMP circuit defines a cancer stem cell-like aggressive subtype of hepatocellular carcinoma. Hepatology 2015; 61: 574–584.
19. Jung KH, Zhang J, Zhou C, Shen H, Gagea M, Rodriguez-Aguayo C et al. Differentiation therapy for hepatocellular carcinoma: Multifaceted effects of miR-148a on tumor growth and phenotype and liver fibrosis. Hepatology 2016; 63: 864–879.

20. Han H, Sun D, Li W, Shen H, Zhu Y, Li C et al. c-Myc-MicroRNA functional feedback loop affects hepatocarcinogenesis. Hepatology 2015; 57: 2378–2389.
21. Han H, Li W, Shen H, Zhang J, Zhu Y, Li Y. microRNA-129-5p, a c-Myc negative target, affects hepatocellular carcinoma progression by blocking the Warburg effect. J Mol Cell Biol 2016; 8: 400–410.
22. Han H, Suzuki K, Komatsu H, Ueda M, Masuda T, Uchi R et al. Decreased expression of fructose-1,6-bisphosphatase associates with glucose metabolism and tumor progression in hepatocellular carcinoma. Cancer Res 2016; 76: 3265–3276.
23. Uemura A, Park EJ, Taniuchi K, Lee JH, Shalapour S, Valasek MA et al. Liver damage, inflammation, and enhanced tumorigenesis after persistent mTORC1 inhibition. Cell Metab 2014; 20: 133–144.
24. Calo N, Ramadori P, Sobolewski C, Romero Y, Maeder C, Fournier M et al. Stress-activated miR-21/miR-21* in hepatocytes promotes lipid and glucose metabolic disorders associated with high-fat diet consumption. Gut 2016; 65: 1871–1881.
25. Settembre C, De Cegli R, Mansueto G, Saha PK, Vetini F, Vaviliv O et al. TFE3 controls cellular lipid metabolism through a starvation-induced autoregulatory loop. Nat Cell Biol 2013; 15: 647–658.
26. Yoshizawa T, Karim MF, Sato Y, Senokuchi T, Miyata K, Fukuda T et al. SIRT7 controls hepatic lipid metabolism by regulating the ubiquitin-proteasome pathway. Cell Metab 2014; 19: 712–721.
27. Liu TF, Tang JJ, Li PS, Shen Y, Li JG, Miao HH et al. Ablation of gp78 in liver improves hyperlipidemia and insulin resistance by inhibiting SREBP to decrease lipid biosynthesis. Cell Metab 2012; 16: 213–225.
28. Dolfi D, Mantovani R. Targeting the YCCAA1 box in cancer: YB-1 (YBX1) or NF-Y? Cell Death Differ 2013; 20: 676–686.
29. Lasham A, Print CG, Wooley AG, Dunn SE, Braithwaite AW. YB-1: oncoprotein, prognostic marker and therapeutic target? Biochem J 2013; 449: 11–23.
30. Ebert MS, Neilson JR, Sharp PR. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat Methods 2007; 4: 721–726.
31. Horie T, Nishino T, Baba O, Kuwabara Y, Nakao T, Nishiga M et al. Disruption of Dicer1 induces dysregulated fetal gene expression and promotes hepatocarcinogenesis. J Clin Invest 2012; 1289–1344.
32. Bond D, Coppola V, Musumeci M, Addario A, Giulfrida R, Memeo L et al. The miR-15a/miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med 2008; 14: 1271–1277.
33. Horie T, Nishino T, Baba O, Kuwabara Y, Nakao T, Nishiga M et al. MicroRNA-33 regulates steroid regulatory element-binding protein 1 expression in mice. Nat Commun 2013; 4: 2883.
34. Han H, Chen Y, Cheng L, Prochownik EV, Li Y. microRNA-206 impairs c-Myc-driven cancer in a synthetic lethal manner by directly inhibiting MAP3K13. Oncotarget 2016; 7: 16409–16419.
35. Kim HS, Minna JD, White MA. GWAS meets TCGA to illuminate mechanisms of cancer predisposition. Cell 2013; 152: 387–389.

Cell Death and Disease is an open-access journal published by Nature Publishing Group. This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2017

Supplementary Information accompanies this paper on Cell Death and Disease website (http://www.nature.com/cddis)